### Analysis:

Johnson & Johnson (JNJ) reported strong financial results for 2016, with sales of $71.9 billion, a 2.6% increase over the previous year. The company's adjusted net earnings were $18.8 billion, marking an 8.5% increase. The company also reported a strong total shareholder return of 15.3% for the year.

The key highlights include:
- **Pharmaceuticals**: Sales grew by 9.9% driven by strong performance in oncology and immunology. Key products like DARZALEX and STELARA continued to perform well.
- **Medical Devices**: Sales grew by 4.7% driven by priority platforms like Electrophysiology and Endocutters.
- **Consumer**: Sales grew by 4.9% driven by strong performance in Beauty and OTC categories.

The company provided guidance for 2017, expecting sales growth of 4% to 5% and adjusted EPS growth of 5% to 7%. The company also noted that it would continue to invest in innovation and may consider strategic acquisitions to drive growth.

### Short-Term Impact:

The stock is likely to experience a positive impact in the short term due to the strong financial results and the optimistic guidance provided by the company. The company's focus on innovation, strategic acquisitions, and operational efficiency is likely to be well-received by investors.

### Conclusion:

The short-term impact on the stock is likely to be **positive**, with the stock expected to rally based on the strong financial results and optimistic guidance provided by the company.

**Rating:** 1